Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 10/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 7/20 | 0.46 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 8/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6498760 | 0.86 | WEE1 (0.48) | WEE1CHEK1SRCESR1KDR | |
| SCHEMBL6202615 | 0.85 | WEE1 (0.47) | WEE1CHEK1SRCESR1KDR | |
| SCHEMBL6504264 | 0.82 | PTGDR2 (0.41) | WEE1CHEK1TDP1 | |
| SCHEMBL6505751 | 0.81 | PTGDR2 (0.41) | WEE1CHEK1TDP1 | |
| SCHEMBL6505761 | 0.81 | PTGDR2 (0.41) | WEE1CHEK1TDP1 | |
| SCHEMBL6503691 | 0.81 | TDP1 (0.40) | WEE1CHEK1TDP1 | |
| SCHEMBL6505681 | 0.81 | NTRK1 (0.43) | WEE1CHEK1TDP1 | |
| SCHEMBL6498347 | 0.81 | TDP1 (0.61) | WEE1CHEK1SRCESR1TDP1 | |
| SCHEMBL6505755 | 0.80 | TDP1 (0.40) | WEE1CHEK1ESR1KDRTDP1 | |
| SCHEMBL6203731 | 0.73 | ESR1 (0.47) | SRCESR1KDRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6844445-B2 | Indenoindolone compounds | LES LABORATOIRES SERVIER (FR) | 2005-01-18 | — | — | US | claimed |
| EP-1245565-B1 | Indenoindolone derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-09-24 | — | — | EP | claimed |
| US-20020173531-A1 | Indenoindolone compounds | LES LABORATOIRES SERVIER (FR) | 2002-11-21 | — | — | US | claimed |
| EP-1245565-A1 | Indenoindolone derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2002-10-02 | — | — | EP | claimed |
| US-6844445-B2 | Indenoindolone compounds | LES LABORATOIRES SERVIER (FR) | 2005-01-18 | — | — | US | disclosed |
| US-20020173531-A1 | Indenoindolone compounds | LES LABORATOIRES SERVIER (FR) | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173531-A1 | Indenoindolone compounds | MTNR1A, MTNR1B, CYP11B1 | WEE1 3618/4885CHEK1 4552/4885SRC 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.